National Institute of Allergy and Infectious Diseases (NIAID): Immunologic Deficiency Syndromes trials

The registry lists 53 Immunologic Deficiency Syndromes studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 11 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 18Phase 2 9Phase 3 3Phase 4 3No phase 25(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationNCT07775313Phase 1/2
• Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without ThymectomyRecruitingNCT07416201
• Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated ColitisRecruitingNCT05333471Phase 1/2
• Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisRecruitingNCT02190266
• Natural History Study of SCID DisordersEnrolling by invitationNCT01186913
• The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known ImmunocompromiseRecruitingNCT01011712
• Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ LymphocytopeniaRecruitingNCT00867269
• Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)RecruitingNCT00006150
• Genetic Analysis of Immune DisordersRecruitingNCT00001467
• Detection and Characterization of Host Defense DefectsRecruitingNCT00001355
• Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruitingNCT00001281
• A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult ParticipantsActive, not recruitingNCT05217641Phase 1Results posted
• COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and DysregulationsCompletedNCT04852276Results posted
• Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy AdultsCompletedNCT03783130Phase 1Results posted
• Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeCompletedNCT02231879Phase 2/3Results posted
• Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous DiseaseTerminatedNCT01147042Phase 4Results posted
• Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) SyndromeTerminatedNCT00527878Phase 2Results posted
• Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1TerminatedNCT00490100Phase 1/2Results posted
• Donor Stem Cell Transplantation for Congenital ImmunodeficienciesCompletedNCT00426517Early Phase 1Results posted
• Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune DefectsCompletedNCT04408950
• Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined ImmunodeficiencyStatus unknownNCT03315078Phase 1/2
• Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima PeruCompletedNCT02630082Not applicable
• A Phase I Study of Mozobil in the Treatment of Patients With WHIMSCompletedNCT00967785Phase 1/2
• Screening Protocol for Genetic Diseases of Allergic InflammationCompletedNCT00852943
• Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load MonitoringCompletedNCT00434070
• STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT00263237Phase 1
• Analysis of Immune Responses to HIV VaccinesCompletedNCT00068978
• Computer-Assisted Adherence Program for Patients Taking Anti-HIV DrugsTerminatedNCT00051766Not applicable
• Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)CompletedNCT00028236Phase 1
• Antibody Production in Immune DisordersTerminatedNCT00023504Phase 4
• Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal SymptomsCompletedNCT00015431
• Once-Daily Drug Regimen for HIV-Infected PatientsCompletedNCT00001968Phase 1
• Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex InfectionCompletedNCT00001763Phase 1
• Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected PatientsCompletedNCT00001650
• White Blood Cell Infusions to Treat HIV InfectionCompletedNCT00001647Phase 1
• Voriconazole vs. Amphotericin B in the Treatment of Invasive AspergillosisCompletedNCT00001646Phase 3
• Fluconazole Prophylaxis of Thrush in AIDSCompletedNCT00001542Phase 4
• Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative VolunteersCompletedNCT00001538Phase 1
• Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor AntagonistCompletedNCT00001475Phase 2
• Interleukin-2 Therapy for HIV Infection - Supplemental ProceduresCompletedNCT00001354Phase 2
• Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin PairsCompletedNCT00001353
• Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous InfectionCompletedNCT00000959Not applicable
• A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)CompletedNCT00000958Phase 1
• Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) InfectionCompletedNCT00000955Not applicable
• Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected PatientsCompletedNCT00000733Phase 1
• Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00000726Phase 1
• A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)CompletedNCT00000701Phase 1
• A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCPCompletedNCT00000700Phase 3
• Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected IndividualsCompletedNCT00000684Not applicable
• A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusCompletedNCT00000683Phase 1
• Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000638Not applicable
• Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000636Not applicable
• Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency SyndromeCompletedNCT00000627Not applicable